Suppr超能文献

接受生物疗法的中重度银屑病患者的 BMI 与 PASI 的相关性。

Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy.

机构信息

Department of Internal Medicine, Oldness and Nephrologic Diseases, Division of Dermatology, University of Bologna, Bologna, Italy.

出版信息

Dermatol Ther. 2010 Jan-Feb;23 Suppl 1:S14-9. doi: 10.1111/j.1529-8019.2009.01281.x.

Abstract

Obesity is common in psoriatic patients, and it has been shown to be important for many aspects of the condition. In particular, low-calorie diets can improve the symptoms and response to treatment in pustular psoriasis. The present study investigates the influence of body-weight alteration on the disease's clinical manifestations in moderate to severe psoriasis patients treated with biological drugs. Finally, the influence of a caloric restriction was assessed. This observational transversal study enrolled 33 patients attending our Severe Psoriasis Outpatient Clinic, who were treated with biological drugs. Body Mass Index (BMI) was used as a diagnostic indicator of being overweight and of obesity. Waist circumference was also measured. Body weight and Psoriasis Area Severity Index (PASI) index were measured at follow-up visits at 4 and 8 months. Nonparametric test of Mann-Whitney was used to detect the differences between patient groups. Fisher's exact test was performed to evaluate the different results depending on the therapeutic changes of BMI. There was a strong prevalence of overweight-obese individuals in the group with a mean BMI of 30.59 +/- 6.94. Waist circumference was also above normal in the majority of the patients. Obese patients had a PASI index higher than the average of the whole group (25.03 +/- 12.43), with grade III obese patients having an average PASI of 44 +/- 3.37. At the first and second follow-ups, patients who put on weight did not achieve PASI 50; patients who had a stable weight presented variable response to treatment, while patients who decreased their weight achieved PASI 90 or PASI 75 even when not responding at the first. Further studies are needed to understand if the poor response observed in heavier patients is due to biological drugs pharmacokinetics or because therapy should be BMI based rather than administered in fixed doses, posing then an ethical consideration.

摘要

肥胖在银屑病患者中很常见,并且已经证明它对疾病的许多方面都很重要。特别是低热量饮食可以改善脓疱性银屑病的症状和治疗反应。本研究调查了体重变化对接受生物药物治疗的中重度银屑病患者疾病临床表现的影响。最后,评估了热量限制的影响。这项观察性横断面研究纳入了 33 名在我们的重度银屑病门诊就诊的患者,他们接受了生物药物治疗。体重指数(BMI)用作超重和肥胖的诊断指标。还测量了腰围。在 4 个月和 8 个月的随访中测量体重和银屑病面积严重程度指数(PASI)指数。使用非参数 Mann-Whitney 检验检测患者组之间的差异。进行 Fisher 确切检验以评估根据 BMI 治疗变化的不同结果。在 BMI 平均值为 30.59 +/- 6.94 的组中,超重-肥胖者的患病率很高。大多数患者的腰围也高于正常。肥胖患者的 PASI 指数高于整个组的平均值(25.03 +/- 12.43),III 级肥胖患者的平均 PASI 为 44 +/- 3.37。在第一次和第二次随访中,体重增加的患者未达到 PASI 50;体重稳定的患者对治疗有不同的反应,而体重减轻的患者即使在第一次没有反应时也能达到 PASI 90 或 PASI 75。需要进一步研究以了解在较重的患者中观察到的不良反应是否是由于生物药物的药代动力学所致,或者是否应该根据 BMI 而不是固定剂量进行治疗,这就提出了一个伦理问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验